Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation.
Tarek ZghaibJohn D AllisonChristopher D BarrettJeffrey S ArklesBenjamin D'SouzaJeffrey LuebbertFermin GarciaE Kevin HeistWendy S TzouDavid CallansFrancis E MarchlinskiDavid S FrankelPublished in: Journal of cardiovascular electrophysiology (2023)
In patients on uninterrupted apixaban or rivaroxaban, who develop refractory pericardial bleeding during AF ablation, andexanet can achieve hemostasis thereby avoiding the need for emergent surgery. However, there is a risk of thromboembolism following administration.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- left atrial appendage
- oral anticoagulants
- direct oral anticoagulants
- heart failure
- end stage renal disease
- percutaneous coronary intervention
- newly diagnosed
- ejection fraction
- minimally invasive
- chronic kidney disease
- prognostic factors
- coronary artery bypass
- patient reported outcomes
- venous thromboembolism
- replacement therapy
- pulmonary embolism
- smoking cessation
- mitral valve